 | |  | AdvantaFlex® TPE tubing welds, seals and molds into fittings to reduce leaks. No silicone oils or animal derived components; fewer extractables than other tubing. Made in USA.
| | |
FEATURED STORY
| A team of scientists led by researchers at the UMass Medical School and UMMSM have identified what is likely a key genetic pathway underlying bipolar disorder, a breakthrough that could lead to better drugs for treating bipolar affective disorder, as well as depression and other related mood disorders. Read more...
| |
| | The Genevac Rocket Synergy Series sets a new benchmark in evaporation versatility. The system is able to dry or concentrate up to six 450ml flasks, or 18 ASE® vials, and with a simple rotor switch enable unattended automated batch processing of up to 100 litres per run.
| | |
| NEWS | | A drug that activates targets of the hedgehog signaling pathway, which is lost when bladder cancer invades, could prevent the progression of the disease in humans. Clinical trials are planned. Read more...
| | |
| NEWS | | Astellas Pharma Inc. announced a research collaboration with an investigator at Harvard focused on discovering the pathologic mechanism for retinitis pigmentosa and identification of new therapeutic targets. Read more...
| | |
| | Join us for a free, educational webcast, as Senior Director of Product Development, Dr. Eric Lader leads an in-depth discussion of:
• miRNA Profiling of biofluid samples
• miRNA biomarker discovery
• supporting data for sample to biomarker miRNA analysis
| | |
| NEWS | | In the first study to look at would-be diseases carried by New York City rats, scientists at the Center for Infection and Immunity at Columbia University's Mailman School of Public Health identified bacterial pathogens, including E. coli, Salmonella, and C. difficile, that cause mild to life-threatening gastroenteritis in people. Read more...
| | |
| NEWS | | The dirt in your backyard may hold the key to isolating cancerous tumors and to potential new treatments for a host of cancers. Read more...
| | |
| NEWS | | Medtronic Inc. announced that the first patients have been enrolled in an investigational device exemption (IDE) study of its breakthrough Predictive Low Glucose Management (PLGM) technology, marking a critical step toward development of an artificial pancreas in the U.S. market. Read more...
| |
